XML 14 R4.htm IDEA: XBRL DOCUMENT v3.21.2
Unaudited Condensed Consolidated Statements of Operations and Comprehensive Income - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Net revenue:    
Total net revenue $ 107,442 $ 85,332
Cost of revenue:    
Total cost of revenue [1] 67,918 49,929
Gross profit 39,524 35,403
Operating expenses:    
Research and development [2] 14,382 12,148
Selling and marketing 11,271 8,898
General and administrative 11,460 8,889
Total operating expenses 37,113 29,935
Income from operations 2,411 5,468
Loss on equity method investment, net (340) (28)
Other expense, net (2,668) (4,694)
Income (loss) before provision for income taxes (597) 746
Provision for income taxes 431 344
Net income (loss) $ (1,028) $ 402
Net income (loss) per share - basic $ (0.01) $ 0.00
Net income (loss) per share - diluted $ (0.01) $ 0.00
Weighted average common shares used in computing net income per share:    
Basic 90,838 91,194
Diluted 90,838 91,681
Net income (loss) $ (1,028) $ 402
Foreign currency translation adjustment 231 1,493
Comprehensive income (loss) (797) 1,895
Products    
Net revenue:    
Total net revenue [3] 52,759 31,258
Cost of revenue:    
Total cost of revenue 31,509 18,426
Services    
Net revenue:    
Total net revenue [4] 54,683 54,074
Cost of revenue:    
Total cost of revenue $ 36,409 $ 31,503
[1] Includes cost of revenue from sales to the China joint venture, an equity method investment of $8,044 and $1,944 for the three months ended September 30, 2021 and September 30, 2020, respectively.
[2] Includes chargeback to the China joint venture, an equity method investment related to research and development project of $579 and $0 for the three months ended September 30, 2021 and September 30, 2020, respectively.
[3] Includes sales to the China joint venture, an equity method investment of $5,920 and $2,874 for the three months ended September 30, 2021 and September      30, 2020, respectively. See Note 14.
[4] Includes sales to the China joint venture, an equity method investment of $3,638 and $2,077 for the three months ended September 30, 2021 and September            30, 2020, respectively. See Note 14.